Plain-English translation of NCT06864026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding —a medication that helps with weight loss—to your existing arthritis medication (ixekizumab) can improve your overall health. The study will follow you for up to 12 months to see how well this combination works for managing both your arthritis and your weight.
Many people with psoriatic arthritis also struggle with weight and related health problems like high blood pressure or diabetes. Researchers want to know if combining a weight-loss medication with your current arthritis treatment can address both conditions at the same time.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current arthritis medication while also receiving the new weight-loss medication as injections under your skin. Over 12 months, you'll have regular visits with the research team to monitor how well the combination is working for your arthritis, weight, and overall health. The study takes place in real-world clinical settings, so it mirrors how you'd normally receive care.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States